Company Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-05-28 EDT 5-day change 1st Jan Change
63.94 USD -2.65% Intraday chart for Gilead Sciences, Inc. -4.98% -21.07%

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees: 18,000

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
27,281 100.0 % 27,116 100.0 % -0.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
71.7 %
18,884 69.2 % 19,438 71.7 % +2.93%
Europe
15.9 %
4,469 16.4 % 4,310 15.9 % -3.56%
Other International
12.4 %
3,928 14.4 % 3,368 12.4 % -14.26%

Managers

Managers TitleAgeSince
Chief Executive Officer 59 19-02-28
Director of Finance/CFO 54 15-12-31
Chief Tech/Sci/R&D Officer - 21-04-11
Chief Tech/Sci/R&D Officer 61 19-10-31
Investor Relations Contact - 20-12-31
Corporate Officer/Principal - -
Corporate Officer/Principal 54 22-07-17
Corporate Officer/Principal 57 -
Human Resources Officer 48 17-10-31
Corporate Officer/Principal - 18-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 69 20-10-16
Director/Board Member 71 17-12-31
Director/Board Member 65 01-31
Director/Board Member 70 18-05-08
Director/Board Member 53 20-06-14
Chief Executive Officer 59 19-02-28
Director/Board Member 75 20-01-27
Director/Board Member 56 16-08-18
Director/Board Member 70 20-12-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,245,853,209 1,244,427,084 ( 99.89 %) 0 99.89 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.201 %
114,732,575 9.201 % 7 489 M $
BlackRock Advisors LLC
7.468 %
93,121,321 7.468 % 6 078 M $
Capital Research & Management Co. (World Investors)
6.776 %
84,497,404 6.776 % 5 515 M $
Capital Research & Management Co. (Global Investors)
4.912 %
61,246,366 4.912 % 3 998 M $
57,704,928 4.628 % 3 766 M $
Dodge & Cox
2.660 %
33,167,487 2.660 % 2 165 M $
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.168 %
27,030,078 2.168 % 1 764 M $
Geode Capital Management LLC
2.113 %
26,349,355 2.113 % 1 720 M $
Wellington Management Co. LLP
1.649 %
20,567,752 1.649 % 1 342 M $
Eaton Vance Management
1.445 %
18,013,584 1.445 % 1 176 M $
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000328 %
8,186 0.000328 % 266 849 $
Bram Bradesco Asset Management S/A DTVM
0.000212 %
5,280 0.000212 % 172 119 $
Western Asset Management Company DTVM Ltda.
0.000002 %
54 0.000002 % 1 760 $

Holdings

NameEquities%Valuation
16,707,477 25.35% 474,837,523 $
31,532,781 34.67% 464,477,864 $
6,720,803 12.61% 345,314,858 $
4,126,119 9.57% 65,770,337 $
4,854,443 4.55% 35,583,067 $
5,319,148 20.78% 16,861,699 $
18,759,465 19.43% 15,120,129 $
1,089,468 19.87% 14,555,292 $
16,635,286 14.48% 13,308,229 $
7,345,473 19.90% 7,418,928 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD)

Group companies

NameCategory and Sector
Gilead Sciences Ireland UC
Pharmaceuticals: Major

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.94 USD
Average target price
82.77 USD
Spread / Average Target
+29.46%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Company Gilead Sciences, Inc.